Last reviewed · How we verify

NCT06734676

fMRI-guided Transcranial Magnetic Stimulation Treatment for Parkinson's Disease

Completed NA Last updated 16 December 2024
What this trial tests

NA trial testing Intermittent theta burst stimulation (iTBS) in Parkinson's Disease in 36 participants. Completed in 15 May 2024.

Timeline
29 May 2023
Primary endpoint
28 April 2024
15 May 2024

Quick facts

Lead sponsorChangping Laboratory
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposebasic science
Enrollment36
Start date29 May 2023
Primary completion28 April 2024
Estimated completion15 May 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Changping Laboratory

Who can join

Adults 18 to 75, any sex, with Parkinson's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the efficacy of targeting the newly discovered SCAN versus traditional effector-specific networks in M1 using multimodal imaging and rTMS in patients with Parkinson's disease. The main question it aims to answer is: Is rTMS targeting the SCAN more effective than rTMS targeting effector networks?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Intermittent theta burst stimulation (iTBS)

Trials testing the same drug.

Other recruiting trials for Parkinson's Disease

Currently open trials in the same condition.

Other Changping Laboratory trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06734676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing